Vyome Q3 Loss Narrows to $930K; Material Weaknesses Persist, FDA Seeks More VT-1953 Data
HIND is trading near its 52-week low of $1.529 (6.6% above the low).
Summary
Vyome's Q3 loss narrowed to $930,325 from $8,595,300 and cash rose to $6.96 million, but material weaknesses remain unremediated, the going-concern language persists, and the FDA requested more data on the VT-1953 orphan drug application.
Key Events · Earnings and Guidance · HIND
-
Q3 Loss Narrows Sharply
Net loss was $930,325 for the three months ended September 30, 2026 versus $8,595,300 a year earlier; the prior year included $7,705,533 of transactional fees.
-
Cash Rises on ATM Sales
Cash and cash equivalents reached $6,956,822 at September 30, 2026 from $4,982,333 at December 31, 2025, after $5,285,868 of net proceeds from ATM share sales.
-
Material Weaknesses Unremediated
Management concluded disclosure controls were not effective as of September 30, 2026 due to material weaknesses in policies and procedures, segregation of duties and technical accounting expertise; a new CFO was appointed September 1, 2026 to help remediate.
-
Going Concern and Runway
The company states existing cash funds operating requirements for at least 15 months, including initiation of the VT-1953 pivotal trial, but not completion of the trial or other programs.
Analysis · HIND · Life Sciences
Vyome's quarterly loss shrank sharply to $930,325 from $8,595,300 a year ago, largely because last year carried $7.7 million of one-time merger transactional fees, while cash rose to $6.96 million on $5.29 million of ATM proceeds. Against that, the company still carries unremediated material weaknesses in internal control over financial reporting and a going-concern discussion: management says cash funds at least 15 months of operations but not the full VT-1953 pivotal trial, so another raise is likely. The FDA also asked for more information on the VT-1953 Orphan Drug Designation application in Q3, adding regulatory uncertainty to the lead program.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HIND was trading at $1.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4M. The 52-week trading range was $1.53 to $5.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.